It was recognized, quite early, by the healthcare experts that traditional vaccine manufacturing techniques were unable to meet the rapidly growing COVID-19 vaccine demand. This prompted the biopharmaceutical firms to adopt “smart” vaccines products developed and manufactured using the novel nucleic acid and viral vector biotechnology platform technology. As the pandemic ebbs, the success of the novel platform-based vaccines will trigger a possible extension of this technology to diseases beyond COVID-19. In this context, this work explores and highlights the “smartness” of the novel biotechnology platform-based vaccines to aid the research community in their future vaccine development endeavors.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jul 2022|
All Science Journal Classification (ASJC) codes